Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Azra Blazevic

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Nature Communications|March 6, 2023
Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adultsZachary K Sagawa, Cristina Goman, Aude Frevol, et al.
Frontiers in Immunology|February 6, 2023
The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studiesJohannes B Goll, Steven E Bosinger, Travis L Jensen, et al.
Frontiers in Immunology|March 13, 2023
Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studiesJohannes B Goll, Steven E Bosinger, Travis L Jensen, et al.
Frontiers in Immunology|September 14, 2023
Identification of immunodominant T cell epitopes induced by natural Zika virus infectionChristopher S Eickhoff, Krystal A Meza, Frances E Terry, et al.
Ebiomedicine|June 21, 2016
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 TrialDaniel F Hoft, Azra Blazevic, Asmir Selimovic, et al.
The Journal of Infectious Diseases|November 29, 2023
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In VivoAzra Blazevic, Rachel L Edwards, Mei Xia, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 21, 2025
Accuracy of VIDAS® TB-IGRA in TB patients and individuals with different thresholds of exposureDelia Goletti, Niaz Banaei, Rahul Batra, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Nature Communications|March 6, 2023
Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adultsZachary K Sagawa, Cristina Goman, Aude Frevol, et al.
Frontiers in Immunology|February 6, 2023
The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studiesJohannes B Goll, Steven E Bosinger, Travis L Jensen, et al.
Frontiers in Immunology|March 13, 2023
Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studiesJohannes B Goll, Steven E Bosinger, Travis L Jensen, et al.
Frontiers in Immunology|September 14, 2023
Identification of immunodominant T cell epitopes induced by natural Zika virus infectionChristopher S Eickhoff, Krystal A Meza, Frances E Terry, et al.
Ebiomedicine|June 21, 2016
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 TrialDaniel F Hoft, Azra Blazevic, Asmir Selimovic, et al.
The Journal of Infectious Diseases|November 29, 2023
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In VivoAzra Blazevic, Rachel L Edwards, Mei Xia, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 21, 2025
Accuracy of VIDAS® TB-IGRA in TB patients and individuals with different thresholds of exposureDelia Goletti, Niaz Banaei, Rahul Batra, et al.
Pageof 3